It was a dramatic turnaround for a little-known company that, just one year earlier, had been on the verge of collapse. One of its leading vaccine candidates — to prevent a deadly virus in infants — had failed for the second time in three years. Word spread around the small world of Maryland biotech that Novavax might be closing soon. Its method’s potential to quickly manufacture millions of doses was also attractive to the federal government and Dr. Hatchett’s organization. The success this spring of a clinical trial of Novavax’s flu vaccine boosted confidence in the company.

Source: International New York Times July 16, 2020 14:26 UTC